Filing Analysis
Pharma-Bio Serv, Inc. filed an 8-K to furnish its results of operations for the three and nine months ended July 31, 2025.
📋 Key Facts
- Reporting period: Three and nine months ended July 31, 2025.
- Filing date: September 15, 2025.
- The filing includes a press release (Exhibit 99.1) detailing financial performance.
Pharma-Bio Serv, Inc. filed an 8-K to announce its results of operations for the fiscal quarter ended April 30, 2025.
📋 Key Facts
- The filing is a routine announcement of quarterly results (Item 2.02).
- Reporting period: Quarter ended April 30, 2025.
- Filing date: June 16, 2025.
- The company furnished a press release as Exhibit 99.1.
Pharma-Bio Serv, Inc. held its 2025 Annual Meeting of Stockholders on May 15, 2025. The meeting resulted in the election of a new director and the ratification of the company's independent auditors.
📋 Key Facts
- Howard Spindel was elected as a Class III director with 7,265,978 votes in favor.
- Crowe PR PSC was ratified as the Company's independent certified public accountants for the fiscal year ending October 31, 2025.
- Shareholders voted to hold 'Say on Pay' advisory votes every three years, following a recommendation from the Board.
Pharma-Bio Serv, Inc. filed an 8-K to announce its results of operations for the fiscal quarter ended January 31, 2025.
📋 Key Facts
- Reporting period: Quarter ended January 31, 2025
- Filing date: March 17, 2025
- The filing includes a press release (Exhibit 99.1) regarding financial results.
Pharma-Bio Serv, Inc. filed an 8-K to announce its results of operations for the fiscal year ended October 31, 2024.
📋 Key Facts
- Report date: January 29, 2025
- Reporting period: Fiscal year ended October 31, 2024
- The filing includes a press release (Exhibit 99.1) regarding financial results.
- Signed by Pedro J. Lasanta, CFO.
Pharma-Bio Serv, Inc. announced that its Board of Directors has approved a special dividend of $0.075 per share.
📋 Key Facts
- Special Dividend amount: $0.075 per share.
- Record Date: February 28, 2025 (close of business).
- Payment Date: On or about March 20, 2025.
- Announcement Date: January 29, 2025.
Pharma-Bio Serv, Inc. filed an 8-K to announce its results of operations for the three and nine months ended July 31, 2024.
📋 Key Facts
- Report date: September 16, 2024
- Reporting period: Three and nine months ended July 31, 2024
- The filing includes a press release (Exhibit 99.1) detailing financial results.
Pharma-Bio Serv, Inc. filed an 8-K to announce its results of operations for the fiscal quarter ended April 30, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly results (Item 2.02).
- Reporting period: Quarter ended April 30, 2024.
- Filing date: June 14, 2024.
Pharma-Bio Serv, Inc. held its 2024 Annual Meeting of Stockholders on May 2, 2024. The meeting resulted in the election of two directors and the ratification of the company's independent auditors.
🚩 Red Flags
- Dov Perlysky received a high number of 'Votes Withheld' (8,958,187) relative to his 'Votes For' (7,546,374), suggesting potential shareholder dissatisfaction or lack of confidence in this specific nominee.
📋 Key Facts
- Stockholders approved an amendment to extend the 2014 Long-Term Incentive Plan for ten additional years (until March 31, 2034).
- Kirk Michel was elected as a Class II director with 12,647,540 votes in favor.
- Dov Perlysky was elected as a Class II director with 7,546,374 votes in favor (noting significant withheld votes).
- Crowe PR PSC was ratified as the independent certified public accountants for the fiscal year ending October 31, 2024.
- The Plan Amendment received 7,523,008 votes in favor.
Pharma-Bio Serv, Inc. filed an 8-K to announce its results of operations for the fiscal quarter ended January 31, 2024.
📋 Key Facts
- Report date: March 18, 2024
- Reporting period: Quarter ended January 31, 2024
- The filing consists of a press release (Exhibit 99.1) regarding financial results.
- Signed by Pedro J. Lasanta, CFO.
Pharma-Bio Serv, Inc. filed an 8-K to announce its results of operations for the fiscal year ended October 31, 2023.
📋 Key Facts
- Reporting period: Fiscal year ended October 31, 2023.
- Announcement date: January 29, 2024.
- The filing includes a press release (Exhibit 99.1) detailing financial results.